The Federal Inland Revenue Service evaluates research and development capital expenditures and patent amortization under Sections 26 and 27 of the Companies Income Tax Act alongside Second Schedule capital allowance provisions. Expenses incurred directly for scientific, industrial, or technological research connected with a company trade or business qualify for corporate tax deductions, provided the outlays satisfy the statutory tests of being wholly, reasonably, exclusively, and necessarily incurred for business income generation.
Under Section 26 of CITA, revenue-based research expenditures such as staff salaries, testing materials, and laboratory consumables incurred in the ordinary course of business qualify as fully allowable operating deductions in the year incurred. The statute imposes a regulatory ceiling stipulating that scientific research deductions in any single tax assessment year cannot exceed ten percent of the company total profit assessed before allowing such scientific research deductions.
Capital expenditures incurred in constructing research facilities, acquiring specialized laboratory machinery, or building proprietary pilot manufacturing plants cannot be expensed immediately as revenue outlays. Instead, these long-term technological assets must be capitalized under the Second Schedule of CITA. Companies can claim qualifying research and development capital allowances, comprising initial allowances and annual allowances deducted against taxable profits across statutory asset lifetimes.
Patent development and intellectual property acquisitions receive specialized tax treatment under Nigerian revenue law. Intangible assets such as acquired patents, proprietary software licenses, trademarks, and industrial designs are amortized over their legal or economic useful lives for statutory accounting purposes under International Financial Reporting Standards. However, for Nigerian corporate tax computations, accounting amortization charges on intangible assets are disallowed as non-statutory accounting adjustments under Section 27 of CITA.
To obtain corporate tax relief for patent creation costs, taxpayers must separate scientific development expenditures from formal patent registration and legal defence fees. Legal expenses, filing surcharges, and official disbursements paid to the Trademarks, Patents and Designs Registry at the Federal Ministry of Industry, Trade and Investment represent capital expenditures associated with securing legal monopoly rights. The Federal Inland Revenue Service disallows direct revenue write-offs for patent acquisition costs unless specifically recognized under qualifying capital allowance categories or intellectual property incentive frameworks established by relevant tax statutes.
Where multinational corporate groups conduct collaborative research across jurisdictions, the Nigerian subsidiary must comply strictly with the Income Tax Transfer Pricing Regulations. Cross-border cost-sharing agreements, technical assistance fees, or patent development royalties paid to offshore parent companies require prior regulatory approval from the National Office for Technology Acquisition and Promotion. In the absence of an authentic NOTAP approval certificate, the Federal Inland Revenue Service disallows the royalty deductions outright and subjects the payments to statutory withholding tax assessments at standard statutory rates.
Corporate taxpayers filing corporate income tax returns on the automated TaxPro-Max platform must upload detailed capital allowance schedules, research expenditure breakdowns, and NOTAP certificates where applicable. Reconciliation statements between IFRS financial statement amortization and CITA tax computations must accompany annual tax filings. The tax authority verifies that development costs capitalized under IAS 38 meet strict scientific feasibility criteria before allowing associated capital allowances.
Companies commercializing proprietary patents developed within Nigeria may access pioneer status incentives administered by the Nigerian Investment Promotion Commission under the Industrial Development Income Tax Relief Act. Qualifying technological innovators awarded pioneer status receive complete corporate tax holidays for three years, extendable by up to two additional years upon satisfactory compliance reviews. During the tax-relief holiday, initial and annual capital allowances on research assets are deferred and carried forward to offset taxable profits once the tax-exempt window concludes.
Taxpayers claiming scientific research deductions must prepare and maintain comprehensive technical documentation to withstand Federal Inland Revenue Service tax audits. The tax authorities require audited management accounts, detailed project cost breakdowns, timesheets of technical research staff, proof of regulatory certifications, and patent grant certificates. If the Federal Inland Revenue Service determines that research expenditures represent disguised personal distributions, related-party management fees without Transfer Pricing documentation, or general exploratory outlays unconnected to the core business, the claimed deductions are promptly disallowed and subjected to back-tax assessments with penalty and interest charges.